Diflunisal therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Résumé fourni par la source

Abstract Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by amyloid fibril deposition in the myocardium. Diflunisal, a non-steroidal anti-inflammatory drug, has been investigated for its potential to stabilise transthyretin tetramers and reduce amyloid formation. Purpose We aim to evaluate the safety and efficacy of diflunisal in ATTR-CM through a systematic review and single-arm meta-analysis. Methods We searched PubMed, Embase, and Cochrane Central for studies analysing diflunisal treatment in ATTR-CM. The outcomes of interest included all-cause mortality, discontinuation due to side effects, changes in left ventricular ejection fraction (LVEF), and pro–B-type natriuretic peptide (BNP) levels. Event prevalence and mean differences (MDs) between pre- and post-treatment were pooled using a random-effects model with 95% confidence intervals (CIs). Statistical analyses were performed using R (version 4.3.1). Results We included seven observational studies, comprising 273 patients with ATTR-CM treated with diflunisal. The follow-up period ranged from 2 months to 5 years. The all-cause mortality rate was 7.18% (95% CI: 2.48–19.01; Figure 1A), while the discontinuation rate due to side effects was 9.5% (95% CI: 4.59–18.64). There were no significant differences between pre- and post-treatment with diflunisal in patients with ATTR-CM in both LVEF (MD -0.38, 95% CI: -1.75–0.98; p=0.58; Figure 1B) and BNP levels (MD -29.53; 95% CI: -119.13–60.0; p=0.52). Conclusions In patients with ATTR-CM, treatment with diflunisal was associated with a 7.18% all-cause mortality rate and a 9.5% discontinuation rate due to side effects, with no significant changes observed in LVEF or BNP levels.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.